| Entry |
|
|---|
| Name |
Asenapine maleate (JAN/USAN);
Saphris (TN)
|
|---|
| Product |
|
|---|
| Formula |
C17H16ClNO. C4H4O4
|
|---|
| Exact mass |
401.103
|
|---|
| Mol weight |
401.8402
|
|---|
| Structure |
   |
|---|
| Class |
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
DG01460 alpha2-Adrenergic receptor antagonist
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
|
|---|
| Remark |
| Therapeutic category: | 1179 |
|
|---|
| Efficacy |
Antipsychotic |
|---|
| Disease |
|
|---|
| Comment |
Treatment of psychosis
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP1A2 [HSA: 1544]
|
|---|
| Interaction |
CYP inhibition: CYP2D6 [HSA: 1565]
 |
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AH Diazepines, oxazepines and thiazepines
N05AH05 Asenapine
D02995 Asenapine maleate (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antipsychotics
2nd Generation/Atypical
Asenapine
D02995 Asenapine maleate (JAN/USAN)
Bipolar Agents
Bipolar Agents, Other
Asenapine
D02995 Asenapine maleate (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
117 Psychotropics
1179 Others
D02995 Asenapine maleate (JAN/USAN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D02995 Asenapine maleate (JAN/USAN) <JP/US>
Serotonin
HTR1A
D02995 Asenapine maleate (JAN/USAN) <JP/US>
HTR2A
D02995 Asenapine maleate (JAN/USAN) <JP/US>
HTR2C
D02995 Asenapine maleate (JAN/USAN) <JP/US>
HTR6
D02995 Asenapine maleate (JAN/USAN) <JP/US>
HTR7
D02995 Asenapine maleate (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D02995
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02995
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D02995
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D02995
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 28
1 C8y C 13.9474 -15.0494
2 C1y C 14.8548 -16.0964
3 C1y C 16.2507 -16.0964
4 C8y C 17.0882 -14.9797
5 C8y C 14.2267 -13.6535
6 C8y C 16.7392 -13.6535
7 O2x O 15.4829 -13.0254
8 C8x C 17.7861 -12.6764
9 C8x C 19.1123 -13.0254
10 C8x C 19.4612 -14.4213
11 C8x C 18.4143 -15.3984
12 C8x C 12.6214 -15.4682
13 C8y C 11.5744 -14.5608
14 C8x C 11.8536 -13.1650
15 C8x C 13.1798 -12.7462
16 C1x C 16.7392 -17.4224
17 N1y N 15.6225 -18.2600
18 C1x C 14.4360 -17.4224
19 X Cl 10.2483 -14.9797
20 C1a C 15.6225 -19.6559
21 O6a O 21.2759 -16.2359
22 C6a C 22.6019 -16.2359
23 O6a O 23.2999 -17.3526
24 C2b C 23.2999 -15.0494
25 C2b C 24.9052 -15.0494
26 C6a C 25.6032 -16.2359
27 O6a O 26.9990 -16.2359
28 O6a O 24.9750 -17.4224
BOND 30
1 3 4 1
2 1 5 1
3 4 6 1
4 2 3 1
5 5 7 1
6 1 2 1
7 6 7 1
8 6 8 2
9 8 9 1
10 9 10 2
11 10 11 1
12 4 11 2
13 1 12 2
14 12 13 1
15 13 14 2
16 14 15 1
17 5 15 2
18 3 16 1
19 16 17 1
20 17 18 1
21 2 18 1
22 13 19 1
23 17 20 1
24 21 22 1
25 22 23 2
26 22 24 1
27 24 25 2
28 25 26 1
29 26 27 2
30 26 28 1
|
|---|
